Characterization of the neurogenic vasodilatation elicited by central dopamine receptor stimulation with pergolide.
In the present study, we have employed the procedure of bilateral hindlimb perfusion at controlled flow rates to investigate centrally mediated actions of the dopamine receptor agonist pergolide on hindlimb vascular resistance in anesthetized dogs. Intracisternal administration of pergolide caused sustained hypotension, bradycardia and a decrease in perfusion pressure in the innervated hindlimb, whereas perfusion pressure in the denervated limb was not altered by pergolide. In addition, the pressure-flow curves were shifted to the right in the innervated hindlimb but not in the denervated limb, suggesting that pergolide caused neurogenic dilatation in the hindlimb vasculature. Intravenous administration of the same dose of pergolide elicited transient hypertension and marked vasoconstriction in the denervated limb. Hypotension and neurogenic hindlimb vasodilatation of lesser magnitude than that produced by intracisternal pergolide were seen only 40 to 50 min after administration of i.v. pergolide. The hindlimb vasodilator action of intracisternal pergolide could be antagonized by sulpiride, which suggests that activation of central dopamine receptors was responsible for the action of pergolide. Because the neural innervation to the hindlimb is comprised of sympathetic vasoconstrictor as well as cholinergic and dopaminergic vasodilator fibers, additional experiments were performed to determine the mechanisms involved in the neurogenic vasodilatation caused by pergolide. Treatment with atropine did not alter the neurogenic decrease in the hindlimb vascular resistance produced by pergolide, indicating that activation of cholinergic vasodilator fibers was not responsible for this phenomenon.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D004285:Dogs; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D006614:Hindlimb / Q000098:blood supply; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D010479:Pergolide; D011954:Receptors, Dopamine / Q000187:drug effects*; D013469:Sulpiride / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000502:physiology; D014655:Vascular Resistance / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects*
D000978:Antiparkinson Agents; D004873:Ergolines; D011954:Receptors, Dopamine; D010479:Pergolide; D001285:Atropine; D013469:Sulpiride; D009638:Norepinephrine